VEGF and TKI Kidney Toxicity: Pressure, Protein, Microvasculature

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Monitor whether the renal and vascular abnormalities improve and whether treatment can continue safely. Persistent injury may need additional evaluation.

Blocking VEGF can affect the glomerular endothelium. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Blocking VEGF can affect the glomerular endothelium. VEGF-pathway inhibition — Cancer treatment target; Endothelial injury — Renal microvascular effects; Proteinuria / microangiopathy — Kidney injury signals; Blood pressure change — Monitor alongside urine and function. Assess severity and the specific agent; do not assume identical risk throughout the class. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Targeted cancer therapy has renal targets too

VEGF-pathway inhibition can affect vascular regulation and glomerular integrity. Tyrosine kinase inhibitors vary in selectivity and adverse effects.

Watch for new signals

Rising blood pressure, increasing proteinuria, edema, or reduced kidney function can indicate treatment-related injury.

Look for renal microvascular injury

Record BP and quantify proteinuria; review creatinine, platelets, hemolysis markers, and sediment when TMA is suspected. Kidney-limited TMA may lack striking systemic hemolysis. New major proteinuria or declining filtration should not be dismissed as simply an expected BP effect.

Match intervention to severity

A manageable BP rise may permit continued cancer therapy with treatment and monitoring. Severe hypertension, nephrotic protein loss, or suspected TMA may require interruption, biopsy, or a regimen change coordinated with oncology. Apply the individual drug’s hold rules; there is no universal VEGF/TKI threshold covering every agent.

Avoid a class-wide assumption

A mild pressure rise and a thrombotic microangiopathy are different clinical problems. Agent-specific evidence and cancer benefit matter.

Follow after intervention

Monitor whether the renal and vascular abnormalities improve and whether treatment can continue safely. Persistent injury may need additional evaluation.

Continue learning